IL139571A0 - A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same - Google Patents

A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same

Info

Publication number
IL139571A0
IL139571A0 IL13957199A IL13957199A IL139571A0 IL 139571 A0 IL139571 A0 IL 139571A0 IL 13957199 A IL13957199 A IL 13957199A IL 13957199 A IL13957199 A IL 13957199A IL 139571 A0 IL139571 A0 IL 139571A0
Authority
IL
Israel
Prior art keywords
verotoxin
binds
production
methods
pharmaceutical compositions
Prior art date
Application number
IL13957199A
Other languages
English (en)
Original Assignee
Teijin Ltd
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Ltd, Protein Design Labs Inc filed Critical Teijin Ltd
Publication of IL139571A0 publication Critical patent/IL139571A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL13957199A 1998-05-20 1999-05-19 A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same IL139571A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8657098P 1998-05-20 1998-05-20
PCT/US1999/011179 WO1999059629A1 (en) 1998-05-20 1999-05-19 Humanized antibodies that recognize verotoxin ii and cell line producing same

Publications (1)

Publication Number Publication Date
IL139571A0 true IL139571A0 (en) 2002-02-10

Family

ID=22199443

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13957199A IL139571A0 (en) 1998-05-20 1999-05-19 A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same
IL139571A IL139571A (en) 1998-05-20 2000-11-09 A human antibody that binds to lorotoxin processes its preparation and pharmaceutical preparations containing it

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL139571A IL139571A (en) 1998-05-20 2000-11-09 A human antibody that binds to lorotoxin processes its preparation and pharmaceutical preparations containing it

Country Status (20)

Country Link
US (1) US7846435B1 (ja)
EP (1) EP1079856B1 (ja)
JP (1) JP4044733B2 (ja)
KR (1) KR100548167B1 (ja)
CN (1) CN1330375C (ja)
AT (1) ATE335504T1 (ja)
AU (1) AU748852B2 (ja)
BR (1) BR9910589A (ja)
CA (1) CA2328485C (ja)
DE (1) DE69932719T2 (ja)
DK (1) DK1079856T3 (ja)
ES (1) ES2270598T3 (ja)
HK (1) HK1036215A1 (ja)
IL (2) IL139571A0 (ja)
NO (1) NO326197B1 (ja)
NZ (1) NZ508119A (ja)
PT (1) PT1079856E (ja)
RU (1) RU2217166C2 (ja)
WO (1) WO1999059629A1 (ja)
ZA (1) ZA200006370B (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910096B2 (en) 1996-11-15 2011-03-22 Trustees Of Tufts College Human neutralizing antibodies against hemolytic uremic syndrome
EP2019684A4 (en) 2006-04-20 2009-08-26 Jackson H M Found Military Med METHODS AND COMPOSITIONS BASED ON SHIGA TOXIN PROTEIN TYPE 1
JP5773886B2 (ja) 2009-01-23 2015-09-02 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド 志賀毒素タイプ２タンパク質に基づいた方法と組成物
EP3003348B1 (en) * 2013-05-27 2019-07-10 Inmunova S.A. Chimeras of brucella lumazine synthase and beta subunit of ab5 toxins
SG11201605691VA (en) * 2014-01-16 2016-08-30 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3236667B2 (ja) 1991-06-28 2001-12-10 三菱化学株式会社 ヒト型モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ並びに抗腫瘍剤
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
WO1993018784A1 (en) 1992-03-26 1993-09-30 Microcarb, Inc. Monospecific polyclonal antibodies to shiga-like toxins
CA2078716A1 (en) 1992-09-21 1994-03-22 Joyce De Azavedo Attaching and effacing protein of enterohemorrhagic e. coli
US5747272A (en) 1994-02-14 1998-05-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Detection of shiga-like toxins of enterohemoragic Escherichia coli
CA2116179C (en) 1994-02-22 2008-01-08 C. A. Lingwood Verotoxin pharmaceutical compositions and medical treatments therewith
WO1996030043A1 (en) 1995-03-24 1996-10-03 Ophidian Pharmaceuticals Treatment for verotoxin-producing escherichia coli
CA2163716C (en) 1995-11-24 2009-05-19 Clifford A. Lingwood Verotoxin pharmaceutical compositions and medical treatments therewith
DE19641466A1 (de) 1996-10-09 1998-04-16 Biotest Pharma Gmbh Orale Anwendung eines Immunglobulinpräparates zur Prävention des Hämolytischen Urämischen Syndroms sowie Präparat hierfür
WO1998020903A1 (en) * 1996-11-15 1998-05-22 Trustees Of Tufts College Humanized neutralizing antibodies against hemolytic uremic syndrome
US20030170248A1 (en) * 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease

Also Published As

Publication number Publication date
ES2270598T3 (es) 2007-04-01
WO1999059629A1 (en) 1999-11-25
US7846435B1 (en) 2010-12-07
JP2002515230A (ja) 2002-05-28
IL139571A (en) 2009-09-22
KR20010052367A (ko) 2001-06-25
NO20005833L (no) 2001-01-15
ATE335504T1 (de) 2006-09-15
AU748852B2 (en) 2002-06-13
KR100548167B1 (ko) 2006-01-31
CA2328485A1 (en) 1999-11-25
NZ508119A (en) 2003-06-30
ZA200006370B (en) 2001-08-22
CN1330375C (zh) 2007-08-08
HK1036215A1 (en) 2001-12-28
NO20005833D0 (no) 2000-11-17
RU2217166C2 (ru) 2003-11-27
PT1079856E (pt) 2006-12-29
NO326197B1 (no) 2008-10-13
DE69932719D1 (de) 2006-09-21
DE69932719T2 (de) 2007-09-13
DK1079856T3 (da) 2006-12-04
JP4044733B2 (ja) 2008-02-06
EP1079856A1 (en) 2001-03-07
BR9910589A (pt) 2001-01-16
EP1079856A4 (en) 2002-03-13
CA2328485C (en) 2011-05-03
CN1301175A (zh) 2001-06-27
EP1079856B1 (en) 2006-08-09
AU4090499A (en) 1999-12-06

Similar Documents

Publication Publication Date Title
GEP20104922B (en) Antibodies to m-csf
GEP20084484B (en) Antibodies to insulin-like growth factor i receptor
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
DE60130538D1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
EP2360169A3 (en) PSMA antibodies
ES2173130T3 (es) Metodo de fijacion de material al peptido beta-amiloide.
WO1998057994A3 (en) Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
ATE370967T1 (de) Polyspezifische bindemoleküle und deren verwendung
AU2001296594A1 (en) Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
GB2383331A (en) Monoclonal antibody DS6 Tumor-associated antigen CA6 and methods of use thereof
NO20083805L (no) Anvendelse av et antistoff som binder Aβ-peptidsekvenser
HK1071304A1 (en) Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b
EP1135415A4 (en) HUMANIZED ANTIBODIES AGAINST GAMMA INTERFERON
HK1076128A1 (en) Humanized collagen antibodies and related methods
WO2003078468A3 (de) Verwendung einer an cd28 bindenden wirksubstanz zur herstellung einer pharmazeutischen zusammensetzung
WO2003048207A3 (en) Anti-dota antibody
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
WO2008100563A3 (en) Compositions and methods for diagnosing and treating cancer
IL139571A0 (en) A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same
UA41984C2 (uk) Спосіб інгібування утворення тромбів у людини (варіанти), спосіб лікування людини для зниження у людини небезпеки постхірургічних тромботичних ускладнень (варіанти),спосіб лікування тромботичного судинного захворювання у людини (варіанти), фармацевтична композиція, що містить некон'юговане антифібринове моноклональне антитіло мн-1, фармацевтична композиція, що містить некон'югований фрагмент або похідне антифібринового моноклонального антитіла мн-1, набір для лікування людини, що потребує інгібування утворення тромбу
ATE296316T1 (de) Gegen menschliches mcm3-protein gerichtete monoklonale antikörper, verfahren zu deren herstellung und deren verwendung
MXPA02005236A (es) Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos.
WO2002100343A3 (en) N-terminally truncated galectin-3 and antibodies for treating cancer